twitter   linkedin

KMT Hepatech, Inc. provides efficient and cost-effective in vivo research services utilizing our proprietary platform technology of small animal model, the KMT MouseTM.

The KMT MouseTM is a chimeric mouse model with humanized liver with stable human hepatocytes engraftment of up to 95 per cent.

We are proud to acknowledge that generated in KMT MouseTM drug therapy responses parallel those seen in humans during clinical trials.

Due to the expanding interest in the humanized liver mouse model across a wide range of drug development fields, the company now offers services in the following areas:

  • Infectious diseases, such as Hepatitis C, Hepatitis B and Malaria
  • Safety toxicity: early assessment of potential hepatotoxicity in in vivo settings prior to first-in-human studies
  • Characterization of human-type drug and lipoprotein metabolism in in vivo settings prior to first-in-human studies

KMT Hepatech, Inc. owns an international patent portfolio that includes coverage of the uPA chimeric mouse model of HCV infection and on the uPA chimeric mouse for all potential applications including HBV, malaria and studies of toxicity, drug and lipoprotein metabolism.

The KMT MouseTM is your essential tool for therapeutics and vaccine development.

News and Events

  1. European ISSX 2017 Meeting small logo

    14th European ISSX Meeting in Germany

    June 16 2017

    Meet KMT Hepatech representative in Cologne, Germany on June 26-29

  2. BIO International Convention 2017 logo small

    Meet KMT Hepatech at BIO International Convention 2017

    June 14 2017

    Dr. S. Sapelnikova will attend BIO International Convention in San Diego, CA (June 19-22)

  3. hepatitis virus image

    Alberta Virology Conference

    June 01 2017

    KMT Hepatech is proud to sponsor 3rd Li Ka Shing Virology Symposium (June 1-2, 2017, University of Alberta)

  4. »more